Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cardiomyopathy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IQGAP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IQGAP1 Recombinant Protein (WW / IQ / GRD Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or Sf9 expressed. |
View IQGAP1 Products |
| Gene Delivery | IQGAP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and rescue assays. |
View IQGAP1 Products |
| Benchmark Ab | Anti-IQGAP1 Recombinant Antibody High-affinity positive control for immunoprecipitation and Western Blot. |
View IQGAP1 Products |
| Validator | IQGAP1 siRNA Set Target-specific knockdown verification in cell-based assays. |
View IQGAP1 Products |
| Related Target A | Cdc42 Key Rho GTPase regulated by IQGAP1; essential for cell polarity and migration studies. |
View Cdc42 Products |
| Related Target B | Rac1 Downstream effector of IQGAP1 signaling; crucial for actin cytoskeleton remodeling assays. |
View Rac1 Products |
| Related Target C | MAPK1 Mitogen-activated protein kinase 1 (ERK2); scaffolded by IQGAP1 to modulate MAPK signaling. |
View MAPK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Screening | Domain-specific truncated proteins (WW, IQ, GRD) with precise tag options (GST/His) for TR-FRET and AlphaScreen assays. |
| Intracellular Targeting & Delivery Validation | Lentivirus-driven reporter cell lines for real-time tracking of downstream MAPK/AKT activation. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated siRNA tools included. |
| False Positives in Scaffold Disruption | High-purity homologous domain proteins available for off-target counter screening. |
Live IQGAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IQGAP1 therapeutics is intensifying, with major players shifting focus from traditional systemic kinase inhibitors to target-specific scaffolding disruptors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the protein-protein interaction (PPI) interfaces of IQGAP1 to selectively block oncogenic signaling without disrupting basal cellular homeostasis.
By acting as a central hub for the MAPK, AKT, and Wnt pathways, IQGAP1 represents a high-value target for overcoming drug resistance in KRAS and BRAF mutant cancers. Emerging strategies are leveraging small molecule inhibitors, peptide mimetics, and PROTACs to selectively degrade or inhibit this master scaffolding protein.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Collaborations, Biotech Startups | KRAS-Mutant Solid Tumors, Melanoma | High-purity recombinant domain proteins (WW/IQ) for robust high-throughput binding assays. |
| PROTAC / Degrader | Targeted Protein Degradation Pioneers | Refractory Pancreatic & Colorectal Cancers | Sequence-verified full-length proteins to optimize ternary complex formation kinetics. |
| Peptide Mimetics | Oncology Research Institutes | Breast Cancer, Hepatocellular Carcinoma | Lentivirus-mediated stable cell lines to validate intracellular delivery and signaling blockade. |